900.7500 -10.60 (-1.16%)
NSE Jan 02, 2026 15:31 PM
Volume: 148.9K
 

900.75
-1.16%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma has gained 27.89% in the last 1 Year
More from Strides Pharma Science Ltd.
Recommended